Drug Trial Radar · NCT06730750
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Feb 12, 2025
Primary completion
Sep 5, 2026
Study completion Dec 9, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Conditions
- Advanced Solid Tumors
Interventions
BMS-986490Drug
Specified dose on specified days.
BevacizumabDrug
Specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participnats with Adverse Events (AEs)Time frame: Up to 100 days following discontinuation of dosing
- Number of participants with Serious AEs (SAEs)Time frame: Up to 100 days following discontinuation of dosing
- Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteriaTime frame: Up to 28 days after the first treatment of study intervention
- Number of participants with AEs leading to discontinuationTime frame: Up to 100 days following discontinuation of dosing
- Number of deathsTime frame: Up to 100 days following discontinuation of dosing
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Local Institution - 0007
Los Angeles, California
Local Institution - 0017
Grand Rapids, Michigan
Local Institution - 0004
Hackensack, New Jersey
Local Institution - 0006
Pittsburgh, Pennsylvania
Tasman Oncology Research
Southport, Queensland, Australia
Local Institution - 0003
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.